# Corrigendum: Discoidin Domain Receptors: Potential Actors and Targets in Cancer

Marie-Pierre Courageot, Laurent Duca, Laurent Martiny, Emmanuelle

Devarenne-Charpentier, Hassan Rammal, Charles Saby, Kevin Magnien,
Laurence Van-Gulick, Roselyne Garnotel, Emilie Buache, et al.

► To cite this version:

Marie-Pierre Courageot, Laurent Duca, Laurent Martiny, Emmanuelle Devarenne-Charpentier, Hassan Rammal, et al. Corrigendum: Discoidin Domain Receptors: Potential Actors and Targets in Cancer. Frontiers in Pharmacology, 2016, 7, 10.3389/fphar.2016.00346. hal-03150780

HAL Id: hal-03150780

https://cnrs.hal.science/hal-03150780v1

Submitted on 1 Apr 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

# Corrigendum: Discoidin Domain Receptors: Potential Actors and Targets in Cancer

Hassan Rammal, Charles Saby, Kevin Magnien, Laurence Van-Gulick, Roselyne Garnotel, Emilie Buache, Hassan El Btaouri, Pierre Jeannesson and Hamid Morjani *

Extracellular Matrix and Cellular Dynamics, Faculty of Pharmacy, MEDyC Centre National de la Recherche Scientifique
UMR7369, Reims University, Reims, France

**Keywords:** discoidin domain receptors, tyrosine kinase, extracellular matrix, collagen, cell signaling, cancer, targeted therapy

## A corrigendum on

### Discoidin Domain Receptors: Potential Actors and Targets in Cancer

Rammal, H., Saby, C., Magnien, K., Van-Gulick, L., Garnotel, R., Buache, E., et al. (2016). *Front. Pharmacol.* 7:55. doi: 10.3389/fphar.2016.00055

## CORRIGENDUM

Following relevant reader's comments and Editor's request, my co-authors and I would like to add some references which have been unintentionally omitted in some sections of the review. We thank the readers and the Editorial Office for pointing this out and helping us to improve the manuscript.

### “INTRODUCTION SECTION” (PAGE 2)

After surgery, radiation therapy (RT) has long been an integral component of cancer care. It is usually employed to locally eradicate tumor cells as well as alter tumor stroma with either curative or palliative intent (Hodge et al., 2012; Kwilas et al., 2012).

Therefore, current efforts have been focusing on understanding the molecular, cellular, and systemic processes driving cancer initiation, progression, heterogeneity, and metastatic spread (Ramos and Bentires-Alj, 2015; Semenova et al., 2015).

As a major part of the tumor ECM, type I collagen exhibits high density and altered architecture in malignant cancer and is causally linked to tumor formation and metastasis (Ren et al., 2014).

Until recently, these effects on tumor cells were exclusively attributed to integrins, a major class of receptors that mediate cell interactions with extracellular matrix components. The identification of the Discoidin Domain Receptor (DDR) family as collagen receptors represents a new paradigm in the regulation of collagen-cell interactions and regulation of tumor progression (Marquez and Olaso, 2014).

DDR1 and DDR2 were initially discovered by homology cloning based on their catalytic kinase domains and were orphan receptors until 1997 when Shrivastava and co-workers and Vogel and co-workers, reported that different types of collagen are functional ligands for these receptors (Leitinger, 2014).

In contrast with classical growth factor tyrosine kinase receptors such as the epithelial growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) which display a rapid and transient activation, DDR1 and DDR2 are unique in that they exhibit remarkably delayed and sustained receptor phosphorylation upon binding to collagen (Iwai et al., 2013).

**OPEN ACCESS**

**Edited and reviewed by:**
Julie Gavard,
French Institute of Health and Medical
Research, France

**\*Correspondence:**
Hamid Morjani
hamid.morjani@univ-reims.fr

**Specialty section:**
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

**Received:** 18 May 2016

**Accepted:** 14 September 2016

**Published:** 30 September 2016

**Citation:**
Rammal H, Saby C, Magnien K, Van-Gulick L, Garnotel R, Buache E, El Btaouri H, Jeannesson P and Morjani H (2016) *Corrigendum: Discoidin Domain Receptors: Potential Actors and Targets in Cancer*. *Front. Pharmacol.* 7:346. doi: 10.3389/fphar.2016.00346
Furthermore, many classical tyrosine kinase receptors (RTKs) undergo negative regulation such as receptor/ligand internalization and subsequent degradation or dephosphorylation by phosphatases (Fu et al., 2013).

In addition, they are uniquely positioned to function as sensors for ECM and to regulate a wide range of cell functions such as migration, cell proliferation, cytokine secretion, and ECM homeostasis/remodeling (Borza and Pozzi, 2014).

## "STRUCTURE, FUNCTION AND REGULATION OF DDRS" SECTION (PAGE 3)

DDRs control important aspects of cell behavior including proliferation, migration, adhesion, and ECM remodeling but are dysregulated in various human diseases. They are both activated by several types of collagen. However, this activation strictly requires collagen to be in its native and triple-helical

conformation. Heat-denatured collagen is not recognized by DDRs (Valiathan et al., 2012; Carafoli and Hohenester, 2013).

Surprisingly, the substitution of five peripheral amino acids in DDR2 with their DDR1 counterparts converts DDR2 into a receptor of type IV collagen (Carafoli and Hohenester, 2013).

## AUTHOR CONTRIBUTIONS

All authors contributed to the designing, writing and the validation of the last version of the manuscript.

## FUNDING

This work was supported by grants from Ligue Contre le Cancer 2015 (CCIR Grand-Est). CS is recipient of PhD fellowships from the French Ministry of Higher Education and Research.

## REFERENCES

* Borza, C. M., and Pozzi, A. (2014). Discoidin domain receptors in disease. *Matrix Biol.* 34, 185-192. doi: 10.1016/j.matbio.2013.12.002

* Carafoli, F., and Hohenester, E. (2013). Collagen recognition and transmembrane signalling by discoidin domain receptors. *Biochim. Biophys. Acta* 1834, 2187-2194. doi: 10.1016/j.bbagap.2012.10.014

* Fu, H. L., Valiathan, R. R., Arkwright, R., Sohail, A., Mihai, C., Kumarasiri, M., et al. (2013). Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. *J. Biol. Chem.* 288, 7430-7437. doi: 10.1074/jbc.R112.444158

* Hodge, J. W., Ardiani, A., Farsaci, B., Kwilas, A. R., and Gameiro, S. R. (2012). The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. *Semin. Oncol. 39*, 323-339. doi: 10.1053/j.seminoncol.2012.02.006

* Iwai, L. K., Payne, L. S., Luczynski, M. T., Chang, F., Xu, H., Clinton, R. W., et al. (2013). Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. *Biochem. J.* 454, 501-513. doi: 10.1042/BJ20121750

* Kwilas, A.R., Donahue, R.N., Bernstein, M.B., and Hodge, J.W. (2012). In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. *Front. Oncol.* 2:104. doi: 10.3389/fonc.2012.00104

* Leitinger, B. (2014). Discoidin domain receptor functions in physiological and pathological conditions. *Int. Rev. Cell Mol. Biol.* 310, 39-87. doi: 10.1016/B978-0-12-800180-6.00002-5

* Marquez, J., and Olaso, E. (2014). Role of discoidin domain receptor 2 in wound healing. *Histol. Histopathol.* 29, 1355-1364. doi: 10.14670/HH-29.1355

* Ramos, P., and Bentires-Alj, M. (2015). Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. *Oncogene* 34, 3617-3626. doi: 10.1038/onc.2014.314

* Ren, T., Zhang, W., Liu, X., Zhao, H., Zhang, J., Zhang, J., et al. (2014). Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia. *J. Pathol.* 234, 526-537. doi: 10.1002/ path.4415

* Semenova, E. A., Nagel, R., and Berns, A. (2015). Origins, genetic landscape, and emerging therapies of small cell lung cancer. *Genes Dev.* 29, 1447-1462. doi: 10.1101/gad.263145.115

* Valiathan, R. R., Marco, M., Leitinger, B., Kleer, C. G., and Fridman, R. (2012). Discoidin domain receptor tyrosine kinases: new players in cancer progression. *Cancer Metastasis Rev.* 31, 295-321. doi: 10.1007/s10555-012- 9346-z

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Rammal, Saby, Magnien, Van-Gulick, Garnotel, Buache, El Btaouri, Jeannesson and Morjani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.